REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) is a clinical-stage biopharmaceutical company focused on central nervous system and neuropsychiatric disorders, including schizophrenia and Parkinson's disease psychosis. The company became a publicly traded entity and filed a Form 10-Q with the SEC on July 3, 2019, under accession number 0001144204-19-033793, reflecting its reporting obligations as a post-merger public company. Reviva operates in the specialty pharmaceutical and CNS therapeutics sector, developing small-molecule drug candidates targeting multiple neuroreceptor pathways. Visit SpacDesk and sign up for full filing history, deal-timeline data, and ongoing coverage of RVPH and hundreds of other SPAC-linked companies.